Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2008

View Archived Issues

IGF-I elevations last over one week after single injection of NNC-126-0083

Recent AstraZeneca patents describe new imaging agents

CNTO-328 demonstrates activity in ovarian cancer trial

New p38alpha MAPK inhibitors disclosed in recent Almirall patent

Recent Takeda patent reports new 5-HT2C receptor agonists for urinary incontinence

Diabetes candidate ARRY-403 to advance to clinical investigation

Ranbaxy submits IND in India to initiate phase I trials of respiratory inflammation candidate

Vernalis receives milestone payment from Servier under oncology drug program

Acusphere's Imagify to be reviewed at FDA Advisory Committee Meeting in December 2008

New agents for treating endocrine disorders divulged in recent patent literature

King Pharmaceuticals extends tender offer until November 2008 to acquire Alpharma

PharmAthene raises USD 13.1 million in strategic equity financing with Panacea Biotec

NVA-237 provides bronchodilation to COPD patients in phase II studies

Differin gel to be launched in Japan for topical treatment of acne vulgaris

Dr. Reddy's subsidiary launches EpiCeram skin barrier emulsion

Lisofylline to be studied in phase II trial to improve islet cell transplant outcomes

Omrix receives EMEA approval for Evicel liquid fibrin sealant

Pfizer launches Macugen for age-related macular degeneration in Japan

Acura and King present top-line results for Acurox in abuse liability

Neurogen reports results from phase II trials of aplindore in RLS and PD

Nile reports interim data from phase IIa CD-NP study in heart failure

TB Alliance and sanofi aventis enter collaboration for new TB drugs

MMRC initiates phase Ib study of elotuzumab in combination with Revlimid and dexamethasone

R&D highlights from the UBS Global Life Sciences Conference in New York: Orexigen Therapeutics

Overall survival and safety data on elesclomol reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...